A Simple Amino Acid May Shield the Lungs of Extremely Preterm Babies

Every year, tens of thousands of babies around the world are born dangerously early, arriving in neonatal intensive care units with lungs that are still under construction. For the most fragile of these infants, those born before 29 weeks of gestation, one of the most feared complications is bronchopulmonary dysplasia, a chronic lung disease that can mean months on oxygen support, repeated hospitalizations, and lifelong respiratory vulnerability. Now, a new study from researchers at the University of Calgary and collaborating institutions suggests that an unexpectedly simple intervention, a dietary supplement of the amino acid L-arginine given during the first month of life, may meaningfully reduce the odds that these tiny patients develop the condition. The findings, published in the Journal of Perinatology, add a provocative new chapter to the search for affordable, accessible therapies against one of neonatology’s most stubborn problems.

The retrospective cohort study, led by Stefani M. Doucette and senior author Abhay Lodha, examined the records of 676 extremely preterm infants born at less than 29 weeks’ gestational age. The researchers compared outcomes before and after their units introduced routine prophylactic arginine supplementation during the first 28 days of life. The primary outcome was bronchopulmonary dysplasia, defined as a continuing need for oxygen at 36 weeks’ postmenstrual age, with severity classified according to the evidence-based criteria developed by Jensen and colleagues. What the team found was striking: the incidence of any bronchopulmonary dysplasia fell from 85 percent to 73 percent after routine supplementation began, a drop of twelve percentage points in a population where nearly every infant had previously been expected to develop some degree of the disease.

Because a before-and-after comparison can be confounded by concurrent changes in care, the investigators went beyond raw numbers. Using multivariable regression analysis to adjust for other factors that influence lung outcomes, they calculated an adjusted odds ratio of 0.50 for any bronchopulmonary dysplasia, with a 95 percent confidence interval of 0.27 to 0.90. In practical terms, even after accounting for other variables, infants exposed to prophylactic arginine had roughly half the odds of developing the disease compared with those who did not receive it. The composite outcome of bronchopulmonary dysplasia or death before 36 weeks’ postmenstrual age was similarly reduced, with an adjusted odds ratio of 0.51 and a confidence interval of 0.28 to 0.91, suggesting that the benefit was not simply an artifact of shifting survival patterns.

Yet the story is not one of unqualified triumph. When the researchers looked specifically at severe disease, grades 2 and 3 on the Jensen scale, the protective signal disappeared. The adjusted odds ratio for severe bronchopulmonary dysplasia was 0.94, with a confidence interval spanning 0.41 to 2.14, a range that includes no effect at all. This pattern suggests that arginine supplementation may primarily prevent milder forms of the disease, or that the study, despite its respectable size, lacked the statistical power to detect a benefit against the most serious outcomes. The distinction matters enormously for families and clinicians, because severe disease carries the heaviest burden of long-term respiratory morbidity, neurodevelopmental impairment, and healthcare cost.

To understand why an amino acid might influence lung development at all, one has to look at the biochemistry of nitric oxide. L-arginine is the obligate substrate for nitric oxide synthase, the enzyme family that converts arginine into nitric oxide, a gaseous signaling molecule with profound effects on vascular tone. In the developing lung, nitric oxide promotes vasodilation of the pulmonary vasculature, supports endothelial function, and helps coordinate the intricate angiogenic crosstalk between blood vessels and the forming air sacs. Extremely preterm infants are known to have low circulating arginine levels, partly because arginine is consumed rapidly by the urea cycle and by arginase enzymes, and partly because the pathways that normally synthesize it are immature. When arginine availability falls, nitric oxide production falters, and the pulmonary vessels that should be remodeling and expanding instead constrict and develop abnormally.

This mechanistic framework is supported by decades of animal research. Studies in hyperoxia-exposed newborn rodents, a standard model of bronchopulmonary dysplasia, have shown that impaired nitric oxide signaling contributes to arrested alveolar growth and pulmonary vascular remodeling, and that restoring downstream intermediates such as L-citrulline can attenuate these injuries. Depletion of arginine by overactive arginase has been implicated in impaired relaxation of lung parenchyma in exposed neonatal animals. Clinical observations add further weight: neonates with pulmonary hypertension have been found to have abnormalities in urea-cycle intermediates and reduced nitric oxide production, linking arginine metabolism directly to pulmonary vascular disease in human newborns.

The arginine hypothesis also fits within a broader, and somewhat humbling, therapeutic history. Inhaled nitric oxide, the direct administration of the very molecule that arginine helps produce, has been tested extensively in preterm infants as a potential preventive therapy for bronchopulmonary dysplasia. Multiple randomized trials and an individual-patient-data meta-analysis failed to demonstrate a consistent benefit, and recent masked randomized controlled trials targeting early pulmonary hypertension have continued to yield uncertain results. The apparent failure of inhaled nitric oxide has pushed researchers toward upstream and systemic approaches, including enteral arginine supplementation, which is cheaper, easier to administer, and may support nitric oxide production throughout the body rather than only in the ventilated airways.

Interestingly, this is not the first time arginine has shown promise in neonatology. Earlier clinical work by some of the same Calgary investigators demonstrated that arginine supplementation could reduce the incidence of necrotizing enterocolitis, a devastating intestinal disease of prematurity, and an updated systematic review has supported that association. The common thread is nitric oxide biology: in the gut, nitric oxide maintains mucosal blood flow and barrier integrity, while in the lung it supports vascular and alveolar development. Arginine’s role as a shared substrate for these protective pathways has made it an attractive candidate for multi-target prophylaxis in the smallest infants, and the new findings extend that logic from the intestine to the lung.

The authors and independent observers alike caution that a retrospective, single-center before-and-after design cannot establish causation. Secular trends in neonatal care, including evolving ventilation strategies, caffeine use, surfactant protocols, and nutrition practices, could have contributed to the observed decline in disease rates, even with statistical adjustment. The study was approved by the Conjoint Health Research Ethics Board at the University of Calgary with a waiver of informed consent, and the authors declare no competing interests, but the inherent limitations of observational methodology mean that a randomized controlled trial remains the essential next step. Such a trial would need to be powered to detect effects on severe disease and long-term respiratory outcomes, not merely the milder spectrum of the condition.

Nevertheless, the implications of the study are considerable. Bronchopulmonary dysplasia remains one of the most common and consequential morbidities of extreme prematurity, imposing enormous healthcare burdens through prolonged hospitalization, home oxygen therapy, readmissions, and increased mortality in outpatient populations. If a randomized trial confirms the association reported here, neonatal intensive care units would gain a remarkably low-cost, orally administered preventive therapy that could be folded into existing feeding protocols for infants under 29 weeks. For now, the Calgary findings offer something rarer than a cure: a biologically plausible, mechanistically grounded lead in a field where genuine therapeutic advances have been scarce, and a reminder that sometimes the most powerful medicines are the humblest molecules already present in the body’s own chemistry.

Subject of Research: Prophylactic arginine supplementation to prevent bronchopulmonary dysplasia in extremely preterm infants

Article Title: The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants

Article References: Doucette, S. M., Jain, S. K., Amin, H., Benlamri, A., Hussain, M., Tang, S., Bhandari, V., & Lodha, A. (2026). The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02922-4

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02922-4

Keywords: arginine supplementation, bronchopulmonary dysplasia, extremely preterm infants, nitric oxide, neonatology, retrospective cohort study, pulmonary vascular development, chronic lung disease, prematurity, Journal of Perinatology, role, prophylactic